Show simple item record

dc.contributor.authorGill, Jason H.*
dc.contributor.authorLoadman, Paul M.*
dc.contributor.authorShnyder, Steven D.*
dc.contributor.authorCooper, Patricia A.*
dc.contributor.authorAtkinson, Jennifer M.*
dc.contributor.authorRibeiro Morais, Goreti*
dc.contributor.authorPatterson, Laurence H.*
dc.contributor.authorFalconer, Robert A.*
dc.date.accessioned2016-08-17T15:04:58Z
dc.date.available2016-08-17T15:04:58Z
dc.date.issued2014-03-18
dc.identifier.citationGill JH, Loadman Paul M, Shnyder SD et al (2014) Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity against Solid Tumors and Reduced Potential for Cardiovascular Toxicity. Molecular Pharmaceutics. 11(4): 1294-1300.en_US
dc.identifier.urihttp://hdl.handle.net/10454/8823
dc.descriptionNoen_US
dc.description.abstractDevelopment of therapeutic strategies for tumor-selective delivery of therapeutics through exploitation of the proteolytic tumor phenotype has significant scope for improvement of cancer treatment. ICT2588 is a peptide-conjugated prodrug of the vascular disrupting agent (VDA) azademethylcolchicine developed to be selectively hydrolyzed by matrix metalloproteinase-14 (MMP-14) within the tumor. In this report, we extend our previous proof-of-concept studies and demonstrate the therapeutic potential of this agent against models of human colorectal, lung, breast, and prostate cancer. In all tumor types, ICT2588 was superior to azademethylcolchicine and was greater or comparable to standard clinically used agents for the respective tumor type. Prodrug activation in clinical human lung tumor homogenates relative to stability in human plasma and liver was observed, supporting clinical translation potential. A major limiting factor to the clinical value of VDAs is their inherent cardiovascular toxicity. No increase in plasma von Willebrand factor (vWF) levels, an indicator of systemic vascular dysfunction and acute cardiovascular toxicity, was detected with ICT2588, thereby supporting the tumor-selective activation and reduced potential of ICT2588 to cause cardiovascular toxicity. Our findings reinforce the improved therapeutic index and tumorselective approach offered by ICT2588 and this nanotherapeutic approach.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttp://pubs.acs.org/doi/abs/10.1021/mp400760ben_US
dc.subjectCancer therapy; Drug delivery; Nanotherapeutic; Peptide conjugate; Matrix metalloproteinase; Vascular disrupting agenten_US
dc.titleTumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicityen_US
dc.status.refereedYesen_US
dc.date.Accepted2014-03-07
dc.typeArticleen_US
dc.type.versionNo full-text available in the repositoryen_US


This item appears in the following Collection(s)

Show simple item record